Drug profile

The FDA adverse-event record for Mepivacaine

16 FDA reports name Mepivacaine, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2035 of 2,679
by report volume (all drugs)
16
adverse-event reports
18.8%
death-coded share
Cat
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Mepivacaine ranks #1995 of 2679 by total reports (16). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1995
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Mepivacaine has 16 reports now versus 15 in that prior snapshot: 1 more (6.7%).

Report change
+1
Death-coded reports
+0
Death-coded share
−1.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Mepivacaine changes

Signature read: 16 reports place Mepivacaine in the lower third of FDA AER volume (#2035 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
3
Deaths Reported
18.8%
Death-coded share of reports

Active Ingredients

Mepivacaine

Administration Routes

UnknownParenteralIntra-ArticularIntraocularOral

Species Affected

Cat 11
Horse 3
Dog 1
Cattle 1

Most Affected Breeds

Domestic Shorthair 7
Cat (unknown) 2
Crossbred Equine/horse 1
Dachshund (unspecified) 1
Domestic Longhair 1
Cattle (other) 1
Horse (other) 1
Domestic Mediumhair 1
Quarter Horse 1

Most Reported Reactions

Uncoded sign 5
Hiding 5
Dysphoria 4
Dilated pupils 3
Not eating 3
Hyperactivity 3
Vocalisation 3
Behavioural disorder NOS 3
Constipation 3
Increased heart rate 2
Hyperglycaemia 2
Elevated aspartate aminotransferase (AST) 2

Outcome Breakdown

Ongoing
6 (37.5%)
Recovered/Normal
4 (25.0%)
Died
2 (12.5%)
Outcome Unknown
2 (12.5%)
Euthanized
1 (6.3%)
Recovered with Sequela
1 (6.3%)

Mepivacaine: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Mepivacaine (#2035 of 2,679 by report volume); death-coded 18.8%. PlainBreed drug row · report volume stamp 16 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →